C. Debruyne

5.7k total citations · 3 hit papers
49 papers, 3.7k citations indexed

About

C. Debruyne is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, C. Debruyne has authored 49 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in C. Debruyne's work include Lung Cancer Research Studies (20 papers), Lung Cancer Treatments and Mutations (19 papers) and Lung Cancer Diagnosis and Treatment (10 papers). C. Debruyne is often cited by papers focused on Lung Cancer Research Studies (20 papers), Lung Cancer Treatments and Mutations (19 papers) and Lung Cancer Diagnosis and Treatment (10 papers). C. Debruyne collaborates with scholars based in Netherlands, Belgium and Italy. C. Debruyne's co-authors include Giuseppe Giaccone, Jan P. van Meerbeeck, Egbert F. Smit, Bonne Biesma, Rabab Gaafar, Desmond Curran, Franz M.N.H. Schramel, Nico van Zandwijk, Catherine Legrand and Eric A. Van Marck and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

C. Debruyne

47 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma

2002 657 citations C. Debruyne, Patrick Therasse et al. Journal of Clinical Oncology profile →
Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

2005 474 citations Jan P. van Meerbeeck, Rabab Gaafar et al. Journal of Clinical Oncology profile →
Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer

2007 471 citations Jan P. van Meerbeeck, G. Kramer et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Debruyne Netherlands	24	2.4k	1.6k	679	575	531	49	3.7k
Kaitlin M. Woo United States	29	1.2k 0.5×	1.3k 0.8×	295 0.4×	225 0.4×	404 0.8×	66	2.7k
Björn Tavelin Sweden	26	1.3k 0.5×	1.2k 0.7×	853 1.3×	320 0.6×	987 1.9×	68	3.7k
Sandra J. Strauss United Kingdom	30	1.5k 0.6×	1.3k 0.8×	215 0.3×	302 0.5×	844 1.6×	94	3.1k
Urs M. Lütolf Switzerland	26	1.4k 0.6×	683 0.4×	1.1k 1.6×	267 0.5×	715 1.3×	50	3.4k
B. Maat Netherlands	12	1.2k 0.5×	635 0.4×	523 0.8×	243 0.4×	177 0.3×	21	2.1k
José Thomas Belgium	38	1.2k 0.5×	1.5k 0.9×	1.1k 1.5×	188 0.3×	282 0.5×	77	4.3k
Justine V. Cohen United States	22	838 0.3×	2.4k 1.5×	369 0.5×	373 0.6×	516 1.0×	96	3.4k
Ufuk Abacıoğlu Türkiye	25	2.8k 1.2×	1.5k 0.9×	2.6k 3.8×	1.0k 1.8×	409 0.8×	66	4.4k
Simonetta Viviani Italy	33	1.2k 0.5×	1.9k 1.1×	755 1.1×	138 0.2×	364 0.7×	119	4.4k
Stephanie E. Weiss United States	22	987 0.4×	699 0.4×	709 1.0×	326 0.6×	219 0.4×	64	1.7k

Countries citing papers authored by C. Debruyne

Since Specialization

Citations

This map shows the geographic impact of C. Debruyne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Debruyne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Debruyne more than expected).

Fields of papers citing papers by C. Debruyne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Debruyne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Debruyne. The network helps show where C. Debruyne may publish in the future.

Co-authorship network of co-authors of C. Debruyne

This figure shows the co-authorship network connecting the top 25 collaborators of C. Debruyne. A scholar is included among the top collaborators of C. Debruyne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Debruyne. C. Debruyne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dizier, Benjamin, Andrea Callegaro, Muriel Debois, et al.. (2019). A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(7). 1725–1735. 13 indexed citations

Jassem, Jacek, M Yoshimura, Francovito Piantedosi, et al.. (2010). MAGE-A3 GENE EXPRESSION FREQUENCY AND DEMOGRAPHY DATA OF STAGE IB-IIIA NSCLC PATIENTS FROM ONGOING MAGRIT PHASE III TRIAL EVALUATING MAGE-A3 ANTIGEN SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT. Annals of Oncology. 21. 134–134. 6 indexed citations

Pas, Tommaso De, Joo-Hang Kim, Paul Zarogoulidis, et al.. (2009). MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized. Journal of Thoracic Oncology. 4(9). 2 indexed citations

Gérard, Catherine & C. Debruyne. (2009). Immunotherapy in the landscape of new targeted treatments for non‐small cell lung cancer. Molecular Oncology. 3(5-6). 409–424. 24 indexed citations

Zieliński, M., et al.. (2009). 9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC. European Journal of Cancer Supplements. 7(2). 511–512. 3 indexed citations

Zieliński, M., A. Linder, Jubrail Dahabreh, et al.. (2009). MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC): from proof-of-concept to phase III trial (MAGRIT). Lung Cancer. 63. S10–S10. 11 indexed citations

Meerbeeck, Jan P. van, G. Kramer, Paul Van Schil, et al.. (2007). Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 99(6). 442–450. 471 indexed citations breakdown →

Efficace, Fabio, Andrew Bottomley, Egbert F. Smit, et al.. (2006). Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Annals of Oncology. 17(11). 1698–1704. 150 indexed citations

Meerbeeck, Jan P. van, C. Manegold, Rabab Gaafar, et al.. (2004). A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. Journal of Clinical Oncology. 22(14_suppl). 7021–7021. 25 indexed citations

10.

Baas, Paul, Andrea Ardizzoni, Francesco Grossi, et al.. (2003). The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma. European Journal of Cancer. 39(3). 353–357. 46 indexed citations

11.

Smit, Egbert F., P. Lianes, C. Debruyne, et al.. (2003). Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. Journal of Clinical Oncology. 21(21). 3909–3917. 281 indexed citations

12.

Dziadziuszko, Rafał, Andrea Ardizzoni, Pieter E. Postmus, et al.. (2003). Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. European Journal of Cancer. 39(9). 1271–1276. 82 indexed citations

13.

Shepherd, Frances A., Giuseppe Giaccone, Lesley Seymour, et al.. (2002). Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology. 20(22). 4434–4439. 192 indexed citations

14.

Ardizzoni, Andrea, Vivianne C. G. Tjan‐Heijnen, Pieter E. Postmus, et al.. (2002). Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923. Journal of Clinical Oncology. 20(19). 3947–3955. 75 indexed citations

15.

Bernier, J., Jan B. Vermorken, C. Debruyne, et al.. (2002). From chemoprevention and organ preservation programmes to postoperative management. European Journal of Cancer. 38. 75–81. 5 indexed citations

16.

Tjan‐Heijnen, Vivianne C. G., Pieter E. Postmus, Andrea Ardizzoni, et al.. (2001). Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Annals of Oncology. 12(10). 1359–1368. 79 indexed citations

17.

Meerbeeck, Jan P. van, Paul Baas, C. Debruyne, et al.. (1999). A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer. 85(12). 2577–2582. 109 indexed citations

18.

Meerbeeck, Jan P. van, Paul Baas, C. Debruyne, et al.. (1997). 57 Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study. Lung Cancer. 18. 17–18. 3 indexed citations

19.

Postmus, PE, et al.. (1996). Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.. PubMed. 23(5 Suppl 12). 10–3. 20 indexed citations

20.

Penninckx, Freddy, C. Debruyne, B. Lestár, & Raymond Kerremans. (1991). Intraobserver variation in the radiological measurement of the anorectal angle. Abdominal Imaging. 16(1). 73–76. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact